China Biologic Products Holdings Inc operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Biologic Products Holdings Inc with three other
companies in this sector in CHINA :
Hualan Biological Engineering Inc
sales of 3.70 billion Chinese Renmimbi [US$519.06 million]
of which 71%
was Blood Product),
Beijing Tiantan Biologic.
(3.28 billion Chinese Renmimbi [US$460.41 million]
of which 100%
was Blood products), and
Boya Bio-pharmaceutical Group Co Ltd
(2.91 billion Chinese Renmimbi [US$408.07 million]
of which 36%
was Blood Products).
During the year ended December of 2019, sales at
China Biologic Products Holdings Inc were 3.48 billion Chinese Renmimbi (US$487.58 million).
increase of 12.4%
versus 2018, when the company's sales were 3.09 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at China Biologic Products Holdings Inc
(and since 2014, sales have increased a total of 132%).
Sales of Biopharmaceutical Products saw an increase
4.2% in 2019, from
2.80 billion Chinese Renmimbi to 2.91 billion Chinese Renmimbi.